TMS Co

TMS Co Net Tangible Assets

The Net Tangible Assets of TMS Co (4891.T) as of Nov 3, 2026 is 2.77 B JPY. In the previous year, Net Tangible Assets was 2.82 B JPY — a change of -1.62% (lower).

Net Tangible Assets

2.77 BJPY

YoY

-1.62%

Last updated:

Net Tangible Assets of TMS Co is 2026 2.77 B JPY. Net Tangible Assets of TMS Co was 2025 2.82 B JPY. It decreases by -1.62% lower compared to the previous year.

The TMS Co Net Tangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Tangible Assets
Date
Net Tangible Assets
Jan 1, 2021
1.13 B JPY
Jan 1, 2022
2.45 B JPY
Jan 1, 2023
3.71 B JPY
Jan 1, 2024
3.46 B JPY
Jan 1, 2025
2.82 B JPY
Jan 1, 2026
2.77 B JPY
The TMS Co Net Tangible Assets history
YEARNet Tangible AssetsYoY
2.77 BJPY-1.62%
2.82 BJPY-18.56%
3.46 BJPY-6.82%
3.71 BJPY+51.49%
2.45 BJPY+117.31%
1.13 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TMS Co Stock analysis

What does TMS Co do? TMS Co., Ltd. generates revenue through the research and development of pharmaceutical products and medical devices, focusing on drug candidates targeting soluble epoxide hydrolase (sEH). The company develops sEH inhibitors for inflammatory diseases, with its lead candidate TMS-007 undergoing clinical development for acute cerebral infarction. TMS-007 combines anti-inflammatory and thrombolytic effects by inhibiting sEH and acting on plasminogen. The follow-on product TMS-008 is in pre-clinical studies for various inflammatory diseases. The company collaborates with academia and research institutions for R&D results, leveraging external research to advance its pipeline. TMS Co., Ltd. targets the pharmaceutical market for inflammatory disease treatments, focusing on drug candidates with dual mechanisms of action. Its primary customers are pharmaceutical companies and research institutions seeking innovative therapeutic solutions. The company's pipeline includes TMS-007 for acute cerebral infarction and TMS-008 for broader inflammatory conditions, positioning itself in the biopharmaceutical segment. The firm's revenue model relies on advancing its pipeline through clinical and pre-clinical stages, with potential partnerships for further development and commercialization. TMS Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TMS Co stock

Net Tangible Assets of TMS Co is 2.77 B JPY in 2026.

Net Tangible Assets of TMS Co changed from 2.82 B JPY to 2.77 B JPY, representing a -1.62% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Tangible Assets TMS Co since 2006 – with annual values, charts, and detailed analysis.

Net tangible assets equal total assets minus intangible assets, goodwill, and liabilities. They represent the physical asset backing of a company.

Net Tangible Assets's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Tangible Assets's TMS Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TMS Co

All Key Metrics — TMS Co